Syndax Pharmaceuticals, Inc. (SNDX)
20.10
+0.81
(+4.20%)
USD |
NASDAQ |
Sep 01, 16:00
19.95
-0.15
(-0.75%)
Pre-Market: 08:51
Syndax Pharmaceuticals Research and Development Expense (Annual) : 258.78M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 258.78M |
| December 31, 2024 | 241.64M |
| December 31, 2023 | 163.02M |
| December 31, 2022 | 118.04M |
| December 31, 2021 | 87.79M |
| December 31, 2020 | 50.44M |
| December 31, 2019 | 42.99M |
| December 31, 2018 | 60.11M |
| Date | Value |
|---|---|
| December 31, 2017 | 48.20M |
| December 31, 2016 | 31.66M |
| December 31, 2015 | 9.549M |
| December 31, 2014 | 10.18M |
| December 31, 2013 | 3.208M |
| December 31, 2012 | 5.24M |
| December 31, 2011 | 6.087M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics, Inc. | 344.96M |
| Kura Oncology, Inc. | 251.07M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |